PRESS RELEASE 10/10/2023
Sonrai Analytics, a leading AI precision medicine company, today announced the appointment of Paul Jones as Chairman of its Board of Directors. With a remarkable track record in precision medicine and genomics, Paul brings extensive experience and strategic insight to the company.
As Chairman of the Board, Paul will support Sonrai’s aim of accelerating drug discovery and development of diagnostics and personalised therapeutics through AI-driven technology. His appointment marks a significant milestone in Sonrai's journey to advance the field of AI precision medicine.
Paul currently serves as the Chief Executive Officer of Vortex Biosciences, where he is leading a new service-based strategy to capture and isolate circulating tumour cells from blood to support the development of personalised medicines, guide therapy selection and monitor cancer. He has previously worked as Head of Population Genomics at Illumina, Inc. He led the team that created, developed, and actively managed large-scale programmes across more than 50 countries.
Paul was the founding CEO of Genomic Enterprises, the arm of Genomics England responsible for all commercial aspects of the 100,000 Genomes Project. He has also been Director and Leader of Global Life Sciences at Cisco and Head of Global eMarketing & eSales at Novartis.
“We are thrilled to welcome Paul to Sonrai. He has a distinguished career in the life sciences industry characterised by visionary leadership and a commitment to advancing healthcare through cutting-edge technologies.” said Prof. Darragh McArt, CEO-Founder, Sonrai Analytics. “His appointment reflects Sonrai's dedication to driving innovation and excellence in precision medicine and will provide valuable insight as we continue to expand our global footprint."
"We're delighted to welcome Paul as Chairman of Sonrai. Paul has been at the forefront of data-driven and precision healthcare, making him a brilliant fit for the exciting opportunity at Sonrai." Said Luke Smith, Investment Partner at Forward Partners, a leading venture capital firm in London specialising in the tech sector, who led Sonrai's seed plus funding round."
I am delighted to join Sonrai’s Board of Directors as Chairman. I see tremendous potential for us to make a significant impact. The convergence of advanced AI technologies and precision medicine offers unprecedented opportunities for improving patient care, and Sonrai is exceptionally well-positioned to lead in this space.” said Paul Jones, Chairman of Board of Directors, Sonrai Analytics. “I look forward to working closely with the team at Sonrai to propel its mission to advance precision medicine and, ultimately, make a positive difference in the lives of patients worldwide."
NOTES TO EDITOR
About Sonrai Analytics
Sonrai Analytics, founded in 2018 by Prof. Darragh McArt and Dr. Deva Senevirathne, is an AI precision medicine technology company. Sonrai’s flagship product, Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI.
The company partners with biotechnology and pharmaceutical companies to manage and analyse their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently select compounds with the highest potential for success in clinical trials, accelerating drug development and mitigating the risk of failures during human trials.
With a proven track record, Sonrai has successfully deployed its technology with prominent healthcare businesses across the EU and the US. Additionally, they continue to forge strategic partnerships (including NHS) that will further enhance commercial operations and scale impact.
For additional information, please visit: sonraianalytics.com
For media enquiries contact:
Head of Marketing